Literature DB >> 10346416

The use and cost of HIV service provision in England in 1996. National Prospective Monitoring System (NPMS) Steering Group and NPMS Working Party on Costs.

E J Beck1, K Tolley, A Power, S Mandalia, P Rutter, J Izumi, J Beecham, A Gray, D Barlow, P Easterbrook, M Fisher, J Innes, G Kinghorn, B Mandel, A Pozniak, A Tang, D Tomlinson, I Williams.   

Abstract

OBJECTIVE: The aim of the study was to measure the use and estimate the cost of HIV service provision in England. DESIGN AND
SETTING: Standardised activity and case-severity data were collected prospectively in 10 English HIV clinics (5 London and 5 non-London sites) for the periods 1 January 1996 to 30 June 1996 and 1 July 1996 to 31 December 1996 and linked to unit cost data. In total, 5440 patients with HIV infection attended during the first 6 months and 5708 during the second 6 months in 1996. MAIN OUTCOME MEASURES AND
RESULTS: The mean number of inpatient days per patient-year for patients with AIDS was 19.7 [95% confidence interval (CI): 13.7 to 25.7] for January to June and 20.8 (95% CI: 15.3 to 26.4) for July to December 1996. The mean number of outpatient visits for asymptomatic patients with HIV infection was 14.8 (95% CI: 11.9 to 17.6) and 13.3 (95% CI: 10.8 to 15.7) for the respective periods and 16.1 (95% CI: 13.21 to 18.97) and 15.7 (95% CI: 11.2 to 20.2), respectively, for patients with symptomatic non-AIDS (i.e. symptomatic patients with HIV infection but without AIDS-defining conditions). Substantial centre-to-centre variation was observed, suggesting that many clinics can continue the shift from an inpatient- to an outpatient-based service. Cost estimates per patient-year for HIV service provision for 1996 varied from 4695 Pounds (95% CI: 3769 Pounds to 5648 Pounds) for asymptomatic patients, to 7605 Pounds (95% CI: 6273 Pounds to 8909 Pounds) for symptomatic non-AIDS patients to 20,358 Pounds (95% CI: 17,681 Pounds to 23,206 Pounds) for patients with AIDS.
CONCLUSIONS: Different combinations of antiretroviral therapy affect the cost estimates of HIV service provision differently. Anticipated reduction in inpatient-related activity through the increased use of combination antiretroviral therapy will further shift service provision from an inpatient- to outpatient-based service and reduce costs per patient-year. The extent and duration of such effects are currently unknown. The long term effects of combination treatment on the morbidity and mortality patterns of individuals infected with HIV are also currently unknown, as are their implications on the use and cost of HIV service provision. Multicentre databases like the National Prospective Monitoring System (NPMS) will provide healthcare professionals with information to improve existing services and anticipate the impact of new developments.

Entities:  

Mesh:

Year:  1998        PMID: 10346416     DOI: 10.2165/00019053-199814060-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1997-06-25       Impact factor: 56.272

Review 2.  1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee.

Authors:  B Gazzard; G Moyle
Journal:  Lancet       Date:  1998-07-25       Impact factor: 79.321

Review 3.  British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee.

Authors: 
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

4.  The distinction between cost and charges.

Authors:  S A Finkler
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

5.  Hospital care for persons with AIDS in the European Union.

Authors:  M J Postma; K Tolley; R M Leidl; A M Downs; E J Beck; A M Tramarin; Y A Flori; M Santin; F Antoñanzas; H Kornarou; V C Paparizos; M G Dijkgraaf; J Borleffs; A J Luijben; J C Jager
Journal:  Health Policy       Date:  1997-08       Impact factor: 2.980

6.  Changing presentation and survival, service utilization and costs for AIDS patients: insights from a London referral centre.

Authors:  E J Beck; L Whitaker; J Kennelly; C McKevitt; J Wadsworth; D L Miller; C Easmon; A J Pinching; J R Harris
Journal:  AIDS       Date:  1994-03       Impact factor: 4.177

7.  Hospital costs of treating haemophilic patients infected with HIV.

Authors:  J M Kennelly; K H Tolley; A C Ghani; C A Sabin; A K Maynard; C A Lee
Journal:  AIDS       Date:  1995-07       Impact factor: 4.177

8.  A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Authors:  S M Hammer; D A Katzenstein; M D Hughes; H Gundacker; R T Schooley; R H Haubrich; W K Henry; M M Lederman; J P Phair; M Niu; M S Hirsch; T C Merigan
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

9.  Hospital service utilization by HIV/AIDS patients and their management cost in a provincial genitourinary medicine department.

Authors:  A Nageswaran; G R Kinghorn; R N Shen; C J Priestley; T T Kyi
Journal:  Int J STD AIDS       Date:  1995 Sep-Oct       Impact factor: 1.359

10.  Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.

Authors:  E J Beck; K Tolley
Journal:  Int J STD AIDS       Date:  1998-09       Impact factor: 1.359

View more
  7 in total

Review 1.  HIV-1 drug resistance genotyping. A review of clinical and economic issues.

Authors:  C Chaix-Couturier; C Holtzer; K A Phillips; I Durand-Zaleski; J Stansell
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  Use and cost of hospital and community service provision for children with HIV infection at an English HIV referral centre.

Authors:  E J Beck; S Mandalia; R Griffith; J Beecham; M D Walters; M Boulton; D L Miller
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 3.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

4.  Use and cost of antiretrovirals in France 1995-2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database.

Authors:  Yves A Flori; Marc le Vaillant
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  The impact of new antiretroic therapeutic schemes on the cost for AIDS treatment in Greece.

Authors:  J E Kyriopoulos; M A Geitona; V A Paparizos; K K Kyriakis; C A Botsi; N G Stavrianeas
Journal:  J Med Syst       Date:  2001-02       Impact factor: 4.460

6.  Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006.

Authors:  Eduard J Beck; Sundhiya Mandalia; Gary Lo; Peter Sharott; Mike Youle; Jane Anderson; Guy Baily; Ray Brettle; Martin Fisher; Mark Gompels; George Kinghorn; Margaret Johnson; Brendan McCarron; Anton Pozniak; Alan Tang; John Walsh; David White; Ian Williams; Brian Gazzard
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

7.  Cost-effectiveness of highly active antiretroviral therapy in South Africa.

Authors:  Motasim Badri; Gary Maartens; Sundhiya Mandalia; Linda-Gail Bekker; John R Penrod; Robert W Platt; Robin Wood; Eduard J Beck
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.